Overview
- Patients on daraxonrasib plus chemotherapy lived a median 13.2 months compared with about 6.7 months on chemotherapy alone in a late-phase study.
- Daraxonrasib is an oral drug that targets KRAS mutations using a molecular glue approach that binds the cancer-driving protein and blocks its activity.
- The FDA put the drug on a fast-track and authorized expanded access so eligible patients can receive it outside clinical trials.
- Trials reported common side effects, including skin rash, mouth sores, nausea, and diarrhea, with about 30% of patients experiencing severe reactions.
- Revolution Medicines says it is moving quickly to broaden availability as clinicians stress it is not a cure but may add meaningful time and options after standard treatment.